Prime Medicine to Present at Investor Conferences in June
31 Mai 2023 - 2:00PM
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company
committed to delivering a new class of differentiated one-time
curative genetic therapies, today announced that Keith
Gottesdiener, M.D., President and Chief Executive Officer of Prime
Medicine, will participate in three investor conferences in June:
- Jefferies Healthcare Conference: Fireside chat
on Wednesday, June 7, 2023 at 10:00 a.m. ET in New York, NY.
- Goldman Sachs Global Healthcare Conference:
Fireside chat on Monday, June 12, 2023 at 1:20 p.m. PT (4:20 p.m.
ET) in Dana Point, CA.
- 2023 Truist Securities symposia-cel: Panel
discussion titled “In Vivo Cell Therapy Through Targeted Delivery
and Editing” on Tuesday, June 27, 2023 at 3:00 p.m. ET in New York,
NY.
Live audio webcasts of the Jefferies and Goldman Sachs fireside
chats will be available under “Events & Presentations” in the
News & Events section of the Company’s website at
www.primemedicine.com. Replays of the webcasts will be available on
the Prime Medicine website for 30 days following the
presentation.
About Prime MedicinePrime Medicine is a leading
biotechnology company dedicated to creating and delivering the next
generation of gene editing therapies to patients. The Company is
leveraging its proprietary Prime Editing platform, a versatile,
precise and efficient gene editing technology, to develop a new
class of differentiated, one-time, potentially curative genetic
therapies. Designed to make only the right edit at the right
position within a gene while minimizing unwanted DNA modifications,
Prime Editors have the potential to repair almost all types of
genetic mutations and work in many different tissues, organs and
cell types.
Prime Medicine is currently progressing a diversified portfolio
of eighteen programs initially focused on genetic diseases with a
fast, direct path to treating patients or with a high unmet need
because they cannot be treated using other gene-editing approaches.
Over time, the Company intends to maximize Prime Editing’s
therapeutic potential and advance potentially curative therapeutic
options to patients for a broad spectrum of diseases. For more
information, please visit www.primemedicine.com.
Investor ContactHannah DeresiewiczStern
Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media ContactDan Budwick,
1ABdan@1ABmedia.com
Prime Medicine (NASDAQ:PRME)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Prime Medicine (NASDAQ:PRME)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024